Torpedo Diagnostics Information

Torpedo Diagnostics, Inc. is revolutionizing cancer detection, management and cure with a proprietary technology platform that isolates and analyzes whole circulating tumor cells (CTCs). Starting with a non-invasive blood draw, the automated workflow unlocks rich, actionable CTC signatures. The liquid biopsy technology enables screening of high-risk populations, personalized therapy selection, routine monitoring, and disease management. Developed over the past decade in the labs at the MGH Cancer Center and in conjunction with Johnson & Johnson (Janssen), the CTC isolation and analysis workflow is mature and will soon be ready for commercial adoption through clinical trial and testing partnerships. Torpedo Dx was founded by a team of liquid biopsy pioneers and is headquartered inside the historic Navy Yard in Charlestown (Boston), Mass.